PHGDH, the first and rate-limiting enzyme of the SSP, is often overexpressed in cancer and has been linked to tumorigenesis as well as poor diagnosis in different cancers [45–48], identifying PHGDH as an interesting pharmaceutical target [47, 49, 50]. The gene discussed is PHGDH; the disease is cancer.